Pharmacogenomics-guided therapy for essential hypertension: a multi-center randomized controlled open-label trial.

ABSTRACT:

Background

The advent of pharmacogenomics-guided antihypertensive therapy represents a paradigm shift in hypertension management. This study aimed to investigate the prevalence of relevant genetic variants among hypertensive patients in Hunan Province, China, and evaluate the efficacy of genotype-directed vs. clinically guided therapy.

Methods

A total of 2,702 patients with essential hypertension from 14 hospitals were enrolled and evenly randomized to either a control group receiving standard care or an experimental group receiving pharmacogenomics-tailored medication. Genetic variants in seven gene loci (ADRB1, CYP2D6, CYP3A5, CACNA1C, CYP2C9, ACE, ADD1) associated with five major drug classes were analyzed. Blood pressure a

SUBMITTER: Wu S 

PROVIDER: S-EPMC13632465 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature